Novel therapies for metastatic castrate-resistant prostate cancer

Recent advances in tumor biology have made remarkable achievements in the development of therapy for metastatic castrate-resistant prostate cancer. These advances reflect a growing appreciation for the role of the tumor microenvironment in promoting prostate cancer progression. Prostate cancer is no...

Full description

Saved in:
Bibliographic Details
Published in:JNCI : Journal of the National Cancer Institute Vol. 103; no. 22; p. 1665
Main Authors: Dayyani, Farshid, Gallick, Gary E, Logothetis, Christopher J, Corn, Paul G
Format: Journal Article
Language:English
Published: United States 16.11.2011
Subjects:
Androstenes
Androstenols - pharmacology
Angiogenesis Inhibitors - pharmacology
Anilides - pharmacology
Animals
Antibodies, Monoclonal - pharmacology
Antibodies, Monoclonal, Humanized - pharmacology
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Antineoplastic Agents, Hormonal - pharmacology
Atrasentan
Bevacizumab
Biomarkers, Tumor - blood
Bone Remodeling - drug effects
Cancer Vaccines - immunology
Cancer Vaccines - pharmacology
Clinical Trials as Topic
Clusterin - pharmacology
Dasatinib
Denosumab
Endothelin-1 - antagonists & inhibitors
Humans
Immunotherapy - methods
Indoles - pharmacology
Ipilimumab
Male
Mice
Mice, SCID
Molecular Targeted Therapy - methods
Orchiectomy
Phenylthiohydantoin - analogs & derivatives
Phenylthiohydantoin - pharmacology
Prostate-Specific Antigen - blood
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - immunology
Prostatic Neoplasms - pathology
Pyridines - pharmacology
Pyrimidines - pharmacology
Pyrroles - pharmacology
Pyrrolidines - pharmacology
RANK Ligand - antagonists & inhibitors
RANK Ligand - pharmacology
Receptor Cross-Talk - drug effects
Receptors, Androgen - drug effects
Signal Transduction - drug effects
Sunitinib
Taxoids - pharmacology
Thiazoles - pharmacology
Tissue Extracts - pharmacology
Treatment Failure
Tumor Microenvironment - drug effects
Xenograft Model Antitumor Assays
ISSN:1460-2105, 1460-2105
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent advances in tumor biology have made remarkable achievements in the development of therapy for metastatic castrate-resistant prostate cancer. These advances reflect a growing appreciation for the role of the tumor microenvironment in promoting prostate cancer progression. Prostate cancer is no longer viewed predominantly as a disease of abnormally proliferating epithelial cells but rather as a disease of complex interactions between prostate cancer epithelial cells (epithelial compartment) and the surrounding tissues (stromal compartment) in which they reside. For example, prostate cancers frequently metastasize to bone, an organ that contains a microenvironment rich in extracellular matrix proteins and stromal cells including hematopoietic cells, osteoblasts, osteoclasts fibroblasts, endothelial cells, adipocytes, immune cells, and mesenchymal stem cells. Multiple signaling pathways provide crosstalk between the epithelial and the stromal compartments to enhance tumor growth, including androgen receptor signaling, tyrosine kinase receptor signaling, and immune surveillance. The rationale to disrupt this "two-compartment" crosstalk has led to the development of drugs that target tumor stromal elements in addition to the cancer epithelial cell.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1460-2105
1460-2105
DOI:10.1093/jnci/djr362